Scientists have created the most comprehensive map to date of the genetic mutations that fuel cancer — opening the door to extending precision treatments to thousands more patients and offering clues as to why bowel cancer rates are rising in younger people. The landmark… Read More
An international collaboration is set to evaluate chemotherapeutic toxicity in human organoids, aiming to generate safer and more effective cancer therapeutics. iXCells Biotechnologies, a provider of human cell-based solutions and iPSC services, has announced it has joined the collaboration alongside Rosebud Biosciences, Kantify and Incite. The project will… Read More
Scientists have engineered new ‘supercharged’ immune cells that could attack prostate cancer more effectively. Researchers at UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, have engineered a new class of ‘supercharged’ T cells that are stronger, longer lasting, and… Read More
Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate cancer cells—an important process that may help explain how some tumours progress and become resistant to treatment. The study, led by Ziying Liu, a former student in the lab of Fen… Read More
Biotechnology company Outrun Therapeutics has announced its lead programme for the treatment of HPV positive head and neck cancer. The company has selected an E6AP inhibitor strategy as the lead programme from its first-in-class therapeutic pipeline, developed through its proprietary XL discovery platform. The platform has been… Read More
The first patient has been dosed in a treatment for ROR1-positive blood cancers. NVG-222 is a bispecific T-cell engager targeting ROR1 and CD3, developed by biotechnology company NovalGen. The drug is the first therapeutic candidate to use NovalGen’s proprietary AutoRegulation technology, an innovation designed to mitigate excessive… Read More
New research published in the Clinical Lymphoma, Myeloma & Leukemia journal has confirmed that Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are promising therapeutic targets for the treatment of multiple myeloma. These antigens are present on malignant plasma cells but… Read More
A new study has uncovered an unexpected molecular player that helps make cancer cells stress-resilient. Researchers have identified the enzyme DHX8 as a crucial regulator of the stress‑response protein HSF1, which may have potential to open new avenues for future drug development. The… Read More
Biotechnology firm Theolytics has been awarded €8 million research funding through the Horizon Europe programme, to support expansion of the OCTOPOD‑IV Phase IIa trial in platinum‑resistant ovarian cancer. The trial will evaluate THEO‑260 — a next‑generation oncolytic immunotherapy designed… Read More
A £19 million ($25 million) UK programme is set to power the recycling of nuclear materials to develop cutting edge treatments for cancer. Led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the project will use a radionuclide called lead-212 to create… Read More
Researchers have identified a gene which could provide new routes for breast cancer treatment. Scientists from the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research (ICR), London and the Breast Cancer Now Research Unit at King’s College London, have uncovered a new weakness in triple… Read More
Roche has announced that its Phase III persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed. The trial assessed giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal… Read More
C-Further has unveiled its first early-stage therapeutic programmes dedicated to paediatric oncology indications. The international consortium is set to advance CF-012 for the treatment of Ewing sarcoma, in collaboration with investigators at UVA Comprehensive Cancer Center, Dana-Farber Cancer Institute and Mass General Brigham, and has also partnered with MiNK Therapeutics to… Read More
A new anti-tumour treatment for metastatic solid tumours has achieved encouraging results in a Phase I clinical trial. DT-9081, developed by biopharmaceutical company Kainova Therapeutics, is a proprietary, oral small molecule EP4 receptor (EP4R) antagonist in patients with advanced, recurrent, and metastatic solid tumours. According to Kainova, the… Read More
An advanced imaging platform could “accelerate” the treatment of childhood brain tumours, research reveals. Scientists at The Institute of Cancer Research, London have developed a new preclinical platform for studying aggressive childhood brain tumours, using advanced imaging to show how closely experimental models mirror the disease seen… Read More
The types of fats we consume directly impacts the survival and strength of the body’s immune cells and ability to fight disease, researchers have found. A University of Queensland team led an international collaboration that found diet could change the fat composition inside… Read More
